Taysha Gene Therapies (TSHA) Interest Coverage Ratio Growth (1y) (2021 - 2026)
Taysha Gene Therapies (TSHA) Interest Coverage Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | -347.04% |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - | - |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 73.00% |
| 10 | Taysha Gene Therapies | 2.08 Bn | 2.08 Bn | - | 69.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.84% |
| Dec 31, 2025 | -45,984.09% |
| Sep 30, 2025 | -22.73% |
| Jun 30, 2025 | 54.12% |
| Mar 31, 2025 | -48.02% |
| Dec 31, 2024 | 140.72% |
| Sep 30, 2024 | 40.30% |
| Jun 30, 2024 | -205.13% |
| Mar 31, 2024 | -19.54% |
| Dec 31, 2023 | 52.28% |
| Sep 30, 2023 | 93.68% |
| Jun 30, 2023 | 98.38% |
| Mar 31, 2023 | 97.20% |
| Dec 31, 2022 | -1,257.33% |
| Sep 30, 2022 | 74.70% |
| Jun 30, 2022 | -395.74% |
| Mar 31, 2022 | 66.23% |
| Sep 30, 2021 | -227.64% |
| Mar 31, 2021 | 27.15% |